Nab -paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives

Highlights • Chemotherapy is the mainstay treatment for TNBC but long-term outcomes remain poor. • Nab-paclitaxel, a novel form of paclitaxel, has demonstrated superior efficacy in EBC and MBC. • Emerging evidence suggests nab-paclitaxel may be particularly effective in TNBC. • There’s a strong rati...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reviews Vol. 50; pp. 129 - 141
Main Authors Schettini, Francesco, Giuliano, Mario, De Placido, Sabino, Arpino, Grazia
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.11.2016
Subjects
Albumins - administration & dosage
Albumins - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - administration & dosage
Carboplatin - administration & dosage
Chemotherapy
Chemotherapy, Adjuvant
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Doxorubicin - administration & dosage
Female
Hematology, Oncology and Palliative Medicine
Humans
Nab-paclitaxel
Nanoparticles - therapeutic use
Neoadjuvant Therapy
Paclitaxel - administration & dosage
Paclitaxel - therapeutic use
Triple Negative Breast Neoplasms - drug therapy
Triple-negative breast cancer
Chemotherapy
Nab-paclitaxel
Triple-negative breast cancer
Online AccessGet full text

Cover

More Information
Summary:Highlights • Chemotherapy is the mainstay treatment for TNBC but long-term outcomes remain poor. • Nab-paclitaxel, a novel form of paclitaxel, has demonstrated superior efficacy in EBC and MBC. • Emerging evidence suggests nab-paclitaxel may be particularly effective in TNBC. • There’s a strong rationale and impressive early data for nab-paclitaxel/immunotherapy in TNBC. • Evaluating agents based on therapeutic targets in TNBC subgroups may further improve outcomes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2016.09.004